A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis with CD4 250 Cells/mm3

AIDS Clinical Trials Group National Institute of Allergy and Infectious Diseases NIAID USA0 个研究点目标入组 800 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Inclusion Criteria:
•HIV-infected
•Confirmed or probable TB. More information on the criterion can be found in the protocol.
•Chest x-ray within 30 days prior to study entry
•Current rifampin- or other rifamycin-based TB treatment initiated within 14 days prior to study entry
•CD4 count less than 200 cells/mm3 within 30 days prior to study entry
•Willing to use acceptable methods of contraception while on study drugs and for 6 weeks after stopping these drugs
•Able to swallow oral medications
•Parent of guardian willing to provide informed consent, if applicable

•Exclusion Criteria:
•ART for longer than 7 days prior to study entry or treatment for any period of time with two or more antiretrovirals in combination. Participants who have taken nevirapine or zidovudine during pregnancy are not excluded.
•Allergy or sensitivity to any of the study drugs or their formulations
•History of multidrug-resistant TB
•Receipt of any investigational therapy or chemotherapy within 30 days prior to study entry
•Certain medications
•Pregnancy or breastfeeding

发起方

AIDS Clinical Trials Group National Institute of Allergy and Infectious Diseases NIAID USA